Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1171 to 1185 of 1308 results for social care

  1. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  2. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  3. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.

  4. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  5. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    Discontinued Reference number: GID-TA11117

  6. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  7. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  8. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

  9. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

  10. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

  11. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

  12. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

  13. Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment (HTG756)

    Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.

  14. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  15. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.